AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- Researchers review the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients in a recent issue of Clinical Cancer Research.
According to published research from the Netherlands, "Cytotoxic T-cell immunity directed against melanosomal differentiation antigens is arguably the best-studied and most prevalent form of tumor-specific T-cell immunity in humans. Despite this, the role of T-cell responses directed against melanosomal antigens in disease progression has not been elucidated. To address this issue, we have related the presence of circulating melanoma-specific T cells with disease progression and survival in a large cohort of patients with advanced-stage melanoma who had not received prior treatment."
"In 42 (68%) of 62 patients, melanoma-specific T cells were detected, sometimes in surprisingly large numbers," reported Monique van Oijen and colleagues at the Netherlands Cancer Institute. "Disease progression during treatment was more frequent in patients with circulating melanoma-specific T cells, and mean survival of patients with circulating melanoma-specific T cells was equal to the survival of patients without melanoma-specific T cells."
"These data suggest that the induction of melanosomal ...